Skip to content

Survodutide: Side Effects & Safety

Part of the Survodutide Complete Guide

Partner

Research Peptides

BioLongevity Labs15% Off
Shop Peptides at BioLongevity Labs

We may earn a commission if you purchase through this link, at no extra cost to you.

Overall Safety Profile

Survodutide's side effect profile is consistent with the GLP-1 agonist class, with higher rates of GI events than some comparators. The glucagon component adds modest cardiovascular effects requiring monitoring.

Reported Side Effects

  • Nausea (40–60%): Higher rates than some GLP-1 agonists
  • Vomiting and diarrhea: Common
  • Decreased appetite: Therapeutic but can be excessive
  • Heart rate increase: Mild, glucagon-related
  • ALT elevations: Transient liver enzyme increases in some patients

Important Limitations

Phase 3 data not yet available. Long-term safety beyond 48 weeks unknown. The higher GI event rates may limit tolerability compared to better-tolerated alternatives. Not yet approved for any indication.

Potential Contraindications

  • Personal/family history of MTC or MEN2
  • Severe hepatic impairment
  • Pregnancy and breastfeeding

Researching peptides? We did the hard part.

Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.

Related Guides

PI

Peptides Insider Editorial Team

Our content is reviewed for accuracy and grounded in peer-reviewed research where available. We do not provide medical advice. Always consult a qualified healthcare professional.